Literature DB >> 7508686

Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin.

J A Ember1, S D Sanderson, T E Hugli, E L Morgan.   

Abstract

Interleukin-8 (IL-8) is an important mediator of inflammation and has been shown to be a potent chemotactic/cell activator for polymorphonuclear neutrophils (PMNs). T lymphocytes, and basophils. Cellular sources of IL-8 include monocytes, PMNs, endothelial cells, epithelial cells, and keratinocytes when stimulated by factors such as lipopolysaccharide, IL-1, and tumor necrosis factor-alpha. This report demonstrates that C5a, in addition to being a direct mediator of inflammation, can induce both IL-8 synthesis and high levels of release from monocytes. Natural human C5a and a synthetic C-terminal analogue peptide of C5a each induced IL-8 synthesis and release from CD14+ human peripheral blood mononuclear cells. Antigenic reactivity based on enzyme-linked immunosorbent assay gave evidence that IL-8 was present in the culture supernatants of stimulated peripheral blood mononuclear cells. Proof that supernatant levels of IL-8 attain biologically significant quantities was provided by human PMN chemotaxis assays. The quantity of IL-8 recovered from C5a-activated monocytes in peripheral blood mononuclear cells is up to 1,000-fold greater than that released from comparable numbers of PMNs under similar conditions. Therefore, IL-8 released from C5a-activated monocytes may play a significant role in expanding and prolonging cellular infiltration and activation at sites of infection, inflammation, or tissue injury. This observation suggests an important humoral amplification loop for inflammatory events involving both complement activation and cytokine release.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508686      PMCID: PMC1887151     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

2.  Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes.

Authors:  I M Goldstein; G Weissmann
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

3.  Release of histamine from rat mast cells by the complement peptides C3a and C5a.

Authors:  A R Johnson; T E Hugli; H J Müller-Eberhard
Journal:  Immunology       Date:  1975-06       Impact factor: 7.397

4.  A methodological study of E-rosette formation using AET-treated sheep red blood cells.

Authors:  M Madsen; H E Johnsen
Journal:  J Immunol Methods       Date:  1979-05-10       Impact factor: 2.303

5.  Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes.

Authors:  D E van Epps; D E Chenoweth
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

6.  Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor.

Authors:  E L Morgan; J A Ember; S D Sanderson; W Scholz; R Buchner; R D Ye; T E Hugli
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

7.  Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester.

Authors:  D L Thiele; M Kurosaka; P E Lipsky
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

8.  Potentiation of the primary humoral immune response in vitro by C5a anaphylatoxin.

Authors:  M G Goodman; D E Chenoweth; W O Weigle
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors.

Authors:  M G Goodman; D E Chenoweth; W O Weigle
Journal:  J Exp Med       Date:  1982-09-01       Impact factor: 14.307

View more
  31 in total

1.  The C5a receptor is expressed by human renal proximal tubular epithelial cells.

Authors:  R Zahedi; M Braun; R A Wetsel; B H Ault; A Khan; T R Welch; M Frenzke; A E Davis
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  A major role for neutrophils in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; X Zhou; S J Swartz; J L Troy; J A Fairley; G O Till; L A Diaz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells.

Authors:  A Fayyazi; O Scheel; T Werfel; S Schweyer; M Oppermann; O Götze; H J Radzun; J Zwirner
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

4.  Cardiomyopathy is linked to complement activation.

Authors:  Marina Afanasyeva; Noel R Rose
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

5.  Effects of C5a and FMLP on interleukin-8 production and proliferation of human umbilical vein endothelial cells.

Authors:  H Langeggen; E Johnson; G Hetland
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

6.  The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.

Authors:  Kjetil H Egge; Andreas Barratt-Due; Stig Nymo; Julie K Lindstad; Anne Pharo; Corinna Lau; Terje Espevik; Ebbe B Thorgersen; Tom E Mollnes
Journal:  Clin Exp Immunol       Date:  2015-07-19       Impact factor: 4.330

7.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

9.  Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Jyh Kae Nien; Sam S Edwin; Yeon Mee Kim; Joon Seok Hong; Luis F Goncalves; Lami Yeo; Moshe Mazor; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07

10.  Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Authors:  Edward L Morgan; Brandon N Morgan; Elisabeth A Stein; Elizabeth L Vitrs; Marilyn L Thoman; Sam D Sanderson; Joy A Phillips
Journal:  Vaccine       Date:  2009-10-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.